interferon alfa 2a humano recombinante
chron epigen indÚstria e comÉrcio ltda - interferon alfa 2a - antineoplasico
nevirax
fundaÇÃo ezequiel dias - funed - nevirapina - antiviroticos (inibe replicacao virotica)
coumadin
bristol-myers squibb farmacÊutica ltda - anticoagulantes
alfainterferona 2b
fundaÇÃo oswaldo cruz - alfainterferona 2b - outros produtos com acao imunoprotetora
alkeran
aspen pharma indÚstria farmacÊutica ltda - melfalana - antineoplasicos citotoxicos
cloridrato de valganciclovir
dr. reddys farmacÊutica do brasil ltda - cloridrato de valganciclovir - antiviroticos
mafusa
dr. reddys farmacÊutica do brasil ltda - cloridrato de valganciclovir - antiviroticos
daklinza
bristol-myers squibb farmacÊutica ltda - daclatasvir - antivirais
virbagen omega
virbac s.a. - interferão omega recombinante de origem felina - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. em gatos infectados pelo fiv, a mortalidade foi baixa (5%) e não foi influenciada pelo tratamento.
a curitybina
uniÃo quÍmica farmacÊutica nacional s/a - ceratoliticos e ceratoplasticos